NICE Scientific Advice
NICE-TOPRA 2-day Workshop on Health Technology Assessment
19-20 March 2014
An essential introduction to HTA for regulatory professionals who are starting to get involved in HTA as part of product development plans.
National Parallel Scientific Advice
NICE and MHRA re-launch a parallel advice service for developers of medicinal products with an option to request an advisory input from CPRD.
Devices and diagnostics
We are developing new services targeted to the manufacturers of medical technologies (devices & diagnostics).
Contact us to discuss the most appropriate option for your product.
About NICE Scientific advice
NICE Scientific Advice (SA) provides fee-for-service consultation to pharmaceutical companies. By reviewing early product development plans we can advise companies on whether these will generate relevant evidence for future submissions to NICE.
Based on a briefing book, written questions submitted by the company and a face-to-face meeting, NICE SA provides an advice report. There is a fee for this service.
More recently NICE SA has expanded the range of services we offer to give advice alongside regulators.
Why seek advice?
NICE evaluation programmes require certain types of evidence about the technology being appraised. A company may wish to seek advice from NICE to ensure that their proposed development plans can produce evidence that is relevant for a future NICE evaluation.
When can advice be sought?
Advice can be sought at any time. However, a useful time for requesting scientific advice could be during phase II studies before the planning of phase III studies. The earlier in the development process the less specific the advice can be, and the later in the process the less likely it is that companies will be able to make changes to the design of clinical trials.
This page was last updated: 06 January 2014